Tag: Chemotherapy
Significant tumour response to neoadjuvant therapy in high-risk non-metastatic prostate cancer
Addition of abiraterone to ADT/docetaxel does not increase bone loss
Favourable pathologic response rate with neoadjuvant chemotherapy in high-risk upper tract urothelial carcinoma
Head-to-head: Etoposide and irinotecan equally effective in neuroendocrine carcinoma
Pre-operative chemoradiation versus peri-operative chemotherapy for oesophageal cancer
DCF outperforms standard-of-care for locally advanced oesophageal cancer
No benefit of additional oxaliplatin in elderly patients with mCRC
Prognostic impact of early oxaliplatin discontinuation in colon cancer unravelled
Premenopausal women benefit from adjuvant chemotherapy next to endocrine therapy
Novel conjugate meets primary endpoint
BrighTNess data may change guidelines
Double-positive results for triple-negative metastatic breast cancer
Survival after neoadjuvant therapy with trastuzumab-lapatinib plus chemotherapy
No PEARLs of survival with palbociclib plus endocrine therapy compared with capecitabine, but QoL better
Neoadjuvant chemotherapy potential alternative to neoadjuvant chemoradiotherapy in LARC
Consistent benefit of anti-PD-1 therapy for oesophageal and gastric cancer
HIPEC in gastric cancer with peritoneal metastases
ctDNA highly predictive in HER2-positive, advanced gastric or gastro-oesophageal junction cancer
Nivolumab/ipilimumab continues to provide survival benefit in unresectable MPM
Three-year OS follow-up from CASPIAN trial
Both men with high-risk non-metastatic prostate cancer and men with metastatic prostate cancer benefit from intensified hormone treatment
Better survival with neoadjuvant dose-dense MVAC regimen in MIBC
Pembrolizumab prolongs survival in persistent, recurrent, or metastatic cervical cancer
HRR mutational status is prognostic and predictive biomarker olaparib activity
Neoadjuvant nivolumab plus chemotherapy improves surgical outcomes in NSCLC
Pembrolizumab benefits survival in MSI-H/dMMR metastastic colorectal cancer
Adjuvant chemotherapy does not improve outcome in patients with locally advanced cervical cancer
Panitumumab added to 5-FU/LV effective as maintenance therapy in patients with mCRC
Sustained efficacy of nivolumab/ipilimumab plus 2 cycles of chemotherapy in NSCLC
Platinum-based adjuvant chemotherapy in TNBC is not superior or non-inferior to capecitabine
Benefit of both I-O/chemo combo and I-O/I-O combo over chemotherapy alone in oesophageal squamous cell cancer
Benefit of I-O/chemo combo over chemotherapy alone in advanced GC/GEJC/EAC
Perioperative chemotherapy and neoadjuvant multimodality therapy appear equally effective
Novel imaging biomarkers predict benefit in stage 3 NSCLC treated with chemoradiation and durvalumab
Chemoimmunotherapy is effective in a subset of small cell lung cancer patients
How to avoid chemotherapy overtreatment in breast cancer
ES-SCLC: CASPIAN trial perspectives from Prof. Jonathan Goldman
First-line pembrolizumab shows superior PFS in MSI-H/dMMR mCRC
Short-course radiotherapy with delayed surgery better for elderly rectal cancer patients
Bemarituzumab response for gastric/GEJ cancers correlates with FGFR2b levels
Neoadjuvant pembrolizumab in locally-advanced rectal cancer: primary results
Neoadjuvant chemotherapy does not increase perioperative complications in thoracic oesophageal cancer
Adjuvant nivolumab: good quality-of-life
Preliminary surgery salvage data after watch & wait policy from OPERA trial
Predicting resistance to first-line FOLFOX plus bevacizumab in mCRC using circulating markers
Final OS analyses comparing trifluridine/tipiracil + bevacizumab versus capecitabine + bevacizumab in first-line unresectable mCRC patients noneligible for intensive therapy
Maintenance treatment with cetuximab versus observation in RAS wildtype mCRC
Duloxetine ameliorates oxaliplatin-induced peripheral neuropathy
Borderline resectable pancreatic cancer: phase 2 results
Metastatic pancreatic adenocarcinoma: second-line naI-IRI plus 5-FU/LV
Treatment delay for cholangiocarcinoma adjuvant therapy does not affect OS
Triple negative breast cancer gets positive news: KEYNOTE-522 interim results
KEYNOTE-062: Pembrolizumab combination fails to improve survival in gastric/GEJ cancer
Overcoming the challenges of immunotherapy in non–small cell lung cancer
Neoadjuvant chemotherapy as a potential treatment option in colon cancer
Laparascopic surgery; less morbidity, same survival benefits as open surgery in colorectal cancer with liver metastases
ImPassion130 brings breast cancer into the immunotherapy era
I-O monotherapy
Combo I-O plus chemotherapy
Post-study immunotherapy in MYSTIC
Patient-reported outcomes of first-line nivolumab + ipilimumab in high tumour mutational burden advanced non-small-cell lung cancer
Combination therapies: Where are we in 2018?
